Skip to main content
ASTH logo

ASTH · Astrana Health, Inc. · Documents

Track ASTH — free
Market Cap
$1.61B
Shares
55.80M
Volume · Nov 20 441.03K Avg daily vol (3M) 377.55K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $3.18B up 56.4% 10-K filed Mar 12, 2026 Quarterly report FY2026 Q3 Revenue $1.02B up 7.1% 10-Q filed Nov 6, 2026 Latest results Revenue hits $1,023.6 million as adjusted EBITDA reaches $77.2 million 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue and profit surge as cyber incident remains unresolved

Astrana Health, Inc. reported nine-month revenue of $2,961.2 million, up 33%, and attributable net income of $47.1 million, up $30.6 million. The full impact of the cybersecurity incident remains unquantified.

Revenue $1.02B ▲ 7.1% Net income $12.95M ▲ 3372.4% Diluted EPS $0.26 ▲ 2500.0%
Read from the MD&A section
3 source passages
Revenue for the nine months ended September 30, 2026 was $2,961.2 million, as compared to $2,231.2 million for the nine months ended September 30, 2025, an increase of $730.0 million or 33%. Our net income attributable to Astrana Health, Inc. for the nine months ended September 30, 2026 was $47.1 million, as compared to $16.5 million for the same period in 2025, an increase of $30.6 million. At this time, we are unable to estimate the full potential impact of the incident on our business strategy, operations, financial condition, or results of operations Open the document at this passage
Nov 5
Earnings call
Record results with full-year guidance maintained

Astrana delivered record third-quarter revenue of $1.02 billion and adjusted EBITDA of $77.2 million, up 7% and 13%, respectively. It maintained full-year revenue guidance of $3.9 billion to $4 billion and adjusted EBITDA guidance of $261 million to $274 million.

2 source passages
Revenue in the third quarter reached a record $1.02 billion, up 7% year-over-year, and adjusted EBITDA was a record $77.2 million, up 13% year-over-year, and near the high end of guidance. We now expect revenue of $3.9 billion to $4 billion, adjusted EBITDA of $261 million to $274 million, and free cash flow of $107.5 million to $130 million. Open the document at this passage
Nov 5
Current report 8-K
Revenue hits $1,023.6 million as adjusted EBITDA reaches $77.2 million

Astrana Health reported third-quarter revenue of $1,023.6 million, up 7% year-over-year, net income of $20.3 million and adjusted EBITDA of $77.2 million, up 13%.

Financial results, Regulation FD disclosure Read from the first part of this long document
2 source passages
Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the third quarter ended September 30, 2026. Reports record revenue of $1,023.6 million, up 7% year-over-year, net income of $20.3 million, up 1,782% year-over-year, and record adjusted EBITDA^(1)^ of $77.2 million, up 13% year-over-year for the three months ended September 30, 2026 Open the document at this passage
Sep 23
Current report 8-K
Regulation FD disclosure

Astrana Health updated its corporate presentation on September 23, 2026, raising FY2026 Adjusted EBITDA guidance to $255 – $280M and reaffirming revenue guidance of $3,800 – $4,100M and free cash flow guidance of $105 – $132.5M.

Sep 23
Current report 8-K Events of Sep 22
Material cybersecurity incident

Astrana Health, Inc. deemed a social-engineering incident material on September 22, 2026; it believes private or confidential information may have been accessed, but cannot estimate impact and does not expect a material effect on financial condition or results of operations.

Aug 10
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $972.52M ▲ 48.5% Net income $19.74M ▲ 109.5% Diluted EPS $0.40 ▲ 110.5%
May 8
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $965.1M ▲ 55.6% Net income $14.44M ▲ 115.7% Diluted EPS $0.29 ▲ 107.1%
Apr 17
Proxy statement DEF 14A Meeting Jun 10, 2026
Proxy statement AI summary on its way
Mar 30
Current report 8-K
Other events AI summary on its way
Mar 12
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $3.18B ▲ 56.4% Net income $22.49M ▼ 47.9% Diluted EPS $0.46 ▼ 48.9%
2025
Nov 10
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $956.05M ▲ 99.7% Net income $373K ▼ 97.7% Diluted EPS $0.01 ▼ 97.0%
Aug 7
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $654.81M ▲ 34.7% Net income $9.42M ▼ 50.8% Diluted EPS $0.19 ▼ 52.5%
May 9
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $620.39M ▲ 53.4% Net income $6.69M ▼ 54.9% Diluted EPS $0.14 ▼ 54.8%
Showing 1–50 of 212 documents
Key facts CIK 1083446 CUSIP 03763A207 13F (30d) 218 filings 198 filers Visit website Investor relations